ScreenerHero

LABB Genomma Lab Internacional, S.A.B. de C.V.

BMV · MX · Healthcare · Drug Manufacturers - Specialty & Generic · genommalab.com
14.24MXN-1.32%Mkt Cap: 753.31M $P/E: 8.60

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded pr…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$71.39BUSDP/E 26.9
TAK
Takeda Pharmaceutical Company Limited
$64.15BUSD
GALD
Galderma Group AG
$49.55BUSDP/E 60.3
TEVA
Teva Pharmaceutical Industries Limited
$47.64BUSDP/E 68.1
HLN
Haleon plc
$44.72BUSDP/E 20.8
SDZ
Sandoz Group AG
$40.51BUSDP/E 65.9
HLN
Haleon plc
$44.13BUSDP/E 20.9
ZTS
Zoetis Inc.
$33.07BUSDP/E 13.2
UTHR
United Therapeutics Corporation
$23.76BUSDP/E 19.8
VTRS
Viatris Inc.
$21.42BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.67BUSDP/E 116.3
NBIX
Neurocrine Biosciences, Inc.
$14.43BUSDP/E 20.8
IPN
Ipsen S.A.
$14.04BUSDP/E 24.6
ELAN
Elanco Animal Health Incorporated
$11.34BUSD
RDY
Dr. Reddy's Laboratories Limited
$11.05BUSDP/E 30.1
KRK
Krka, d. d.
$8.63BUSDP/E 19.0
ALKS
Alkermes plc
$7.40BUSDP/E 116.1
HLUN-B
H. Lundbeck A/S
$7.26BUSDP/E 12.4
AMRX
Amneal Pharmaceuticals, Inc.
$6.91BUSDP/E 40.5
HLUN-A
H. Lundbeck A/S
$6.88BUSDP/E 11.8

Key Statistics

Company
Market Cap753.31M USD
Enterprise Value1.04B USD
Revenue (TTM)920.34M USD
Gross Profit582.11M USD
Net Income (TTM)87.98M USD
Revenue/Share17.40 MXN
Last Price14.24 MXN
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.7K
CountryMX
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINMX01LA010006
Valuation
P/E (Trailing)8.60
P/E (Forward)7.23
PEG0.47
EV/EBITDA4.97
EV/Revenue1.14
P/S0.82
P/B1.18
EPS (TTM)1.66
EPS (Forward)1.98
52W Range
12.2228% of range19.48
52W High19.48 MXN
52W Low12.22 MXN
Profitability
Gross Margin63.25%
Oper. Margin19.95%
EBITDA Margin22.86%
Profit Margin9.56%
ROE14.16%
ROA9.10%
ROIC—
ROCE—
Growth
Revenue Growth-6.00%
Earnings Growth3.90%
Cash Flow & Leverage
Operating CF99.88M USD
CapEx (TTM)—
FCF Margin2.57%
FCF Yield3.14%
Net Debt293.53M USD
Net Debt/EBITDA1.40
Net Debt/FCF12.39
Balance Sheet
Debt/Equity66.65
Current Ratio1.41
Quick Ratio1.13
Book Value/Sh12.08 MXN
Cash/Share2.47 MXN
Dividends
Fwd Div Rate0.80 MXN
Trail. Div Rate0.40 MXN
Div. Yield5.62%
5Y Avg Yield3.48%
Payout Ratio48.02%
Ex-Div DateSep 29, 2026
Pay Date—
Splits
Last Split2:1
Split DateAug 3, 2010
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.33 MXN
Upside (mean)+49.8%
Target Range16.00 MXN – 29.00 MXN
16.00+49.8% to mean29.00
# Analysts6
Ownership
Shares Out.977.75M
Float672.56M
Insiders31.05%
Institutions32.11%
Technical
SMA 5013.16 (+8.2%)
SMA 20015.64 (-8.9%)
Beta0.13
S&P 52W Chg15.12%
Avg Vol (30d)3.96M
Avg Vol (10d)4.22M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—